RAPT Therapeutics Inc. announced key management changes following its 2025 annual meeting of stockholders. The company's stockholders approved the 2025 Equity Incentive Plan and the amendment and restatement of the 2019 Employee Stock Purchase Plan, which both became effective immediately. Additionally, it was decided that stockholder advisory votes on executive compensation will occur annually.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapt Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-079023), on May 29, 2025, and is solely responsible for the information contained therein.